1 week Ago By ABMN Staff
Revance Therapeutics, Inc. ( NASDAQ:RVNC – Get Free Report ) has been given a consensus rating of “Hold” by the nine ratings firms that are covering the firm, MarketBeat Ratings reports. Eight research analysts have rated the stock with a hold recommendation and one has given a buy recommendation to the company.
The average twelve-month price target among analysts that have issued a report on the stock in the last year is $8.39. Several analysts have recently commented on the company.
Barclays decreased their price objective on Revance Therapeutics from $7.00 to $3.00 and set an “equal weight” rating for the company in a report on Monday, December 23rd.
Needham & Company LLC reiterated a “hold” rating on shares of Revance Therapeutics in a research note on Friday, January 17th. Finally, StockNews.com started coverage on Revance Therapeutics in a research note on Friday.
They set a “hold” rating on the stock. Read Our Latest Analysis on Revance Therapeutics Revance Therapeutics Price Performance Institutional Inflows and Outflows Several institutional investors have recently modified their holdings of the company. CIBRA Capital Ltd purchased a new stake in shares of Revance Therapeutics in the 4th quarter valued at $3,466,000.
Alpine Global Management LLC acquired a new position in Revance Therapeutics during the fourth quarter valued at $37,000. Two Sigma Investments LP boosted its holdings in Revance Therapeutics by 8.6% in the fourth quarter.
Two Sigma Investments LP now owns 170,136 shares of the biopharmaceutical company’s stock valued at $517,000 after purchasing an additional 13,539 shares during the last quarter. ProShare Advisors LLC grew its position in Revance Therapeutics by 19.3% during the 4th quarter.
ProShare Advisors LLC now owns 75,252 shares of the biopharmaceutical company’s stock worth $229,000 after purchasing an additional 12,155 shares during the period. Finally, Man Group plc raised its stake in shares of Revance Therapeutics by 47.8% during the 4th quarter.
Man Group plc now owns 443,544 shares of the biopharmaceutical company’s stock valued at $1,348,000 after buying an additional 143,544 shares during the last quarter. 97.70% of the stock is currently owned by hedge funds and other institutional investors.
Revance Therapeutics Company Profile ( Get Free Report Revance Therapeutics, Inc, a biotechnology company, engages in the development, manufacture, and commercialization of neuromodulators for various aesthetic and therapeutic indications in the United States and internationally. The company’s lead drug candidate is DAXXIFY (DaxibotulinumtoxinA-lanm) for injection for the treatment of glabellar lines and cervical dystonia; has completed phase II clinical trials to treat upper facial lines, moderate or severe dynamic forehead lines, and moderate or severe lateral canthal lines; and has completed Phase II clinical trials for the treatment of adult upper limb spasticity and plantar fasciitis. Featured Stories Receive News & Ratings for Revance Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Revance Therapeutics and related companies with MarketBeat.
com's FREE daily email newsletter ..
